Financials
| 3rd Quarter Results | Oct. 29, 2025 |
| 2nd Quarter Results | Jul. 30, 2025 |
| 1st Quarter Results | Apr. 30, 2025 |
| GSK plc 2024 Annual Report on Form 20-F | Mar. 03, 2025 |
| GSK publishes Annual Report 2024 | Feb. 27, 2025 |
| 2024 Annual Financial Report | Feb. 27, 2025 |
| Final Results | Feb. 05, 2025 |
Proxies
| Result of AGM | May. 07, 2025 |
| GSK Proxy Form 2025 | Mar. 24, 2025 |
| GSK AGM Notice 2025 | Mar. 24, 2025 |
| Notice of AGM | Mar. 24, 2025 |
| Result of AGM | May. 08, 2024 |
| GSK Proxy Form 2024 | Mar. 25, 2024 |
| GSK AGM Notice 2024 | Mar. 25, 2024 |
Ownership Update
| Director/PDMR Shareholding | Dec. 22, 2025 |
| Transaction in Own Shares | Dec. 22, 2025 |
| Transaction in Own Shares | Dec. 19, 2025 |
| Transaction in Own Shares | Dec. 18, 2025 |
| Transaction in Own Shares | Dec. 17, 2025 |
| Transaction in Own Shares | Dec. 16, 2025 |
| Transaction in Own Shares | Dec. 15, 2025 |
Announcements
| GSK to lower drug prices and expand access in US | Dec. 22, 2025 |
| Exdensur (depemokimab ulla) approved by US FDA | Dec. 17, 2025 |
| Nucala receives positive CHMP opinion for COPD | Dec. 12, 2025 |
| Depemokimab receives positive CHMP opinion | Dec. 12, 2025 |
| Positive CHMP opinion on Arexvy for all adults 18+ | Dec. 12, 2025 |
| Blujepa approved in US for gonorrhoea indication | Dec. 11, 2025 |
| Block Listing Application | Dec. 11, 2025 |
Prospectuses
| GSK plc;GLAXOSMITHKLINE CAPITAL PLC;GSK Capital B.V.;GSK Capital K.K - Base prospectus (debt) | Sep. 07, 2022 |